Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

Zehra Kaymakcalan(Abbott (United States)), Paul Sakorafas(Abbott (United States)), Sahana Bose(Abbott (United States)), Susanne M. Scesney(Abbott (United States)), Limin Xiong(Abbott (United States)), Denise Karaoglu Hanzatian(Abbott (United States)), Jochen Salfeld(Abbott (United States)), Eric H. Sasso(Abbott Fund)

Clinical Immunology

February 2, 2009

10.1016/j.clim.2009.01.002

Cited by 314

Abstract

Related Papers

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

Daniel E. Tracey, Lars Klareskog, Eric H. Sasso et al.|Pharmacology & Therapeutics|2007|1.6k

Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

William J. Sandborn, S. B. Hanauer, Seymour Katz et al.|Gastroenterology|2001|909

A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact

Carl F. Perez, Iris Albert, Kim DeFay et al.|Cell|1990|408

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

Hiroki Mitoma, Takahiko Horiuchi, Hiroshi Tsukamoto et al.|Arthritis & Rheumatism|2008|345

Tumor necrosis factor-α converting enzyme

Roy A. Black|The International Journal of Biochemistry & Cell Biology|2002|343